Citadel Advisors LLC trimmed its holdings in shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 73.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 124,679 shares of the biotechnology company’s stock after selling 350,869 shares during the period. Citadel Advisors LLC owned 0.55% of Concert Pharmaceuticals worth $1,839,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Concert Pharmaceuticals in the 3rd quarter worth about $153,000. Alliancebernstein L.P. acquired a new stake in shares of Concert Pharmaceuticals in the 2nd quarter worth about $174,000. State of Wisconsin Investment Board acquired a new stake in shares of Concert Pharmaceuticals in the 2nd quarter worth about $181,000. The Manufacturers Life Insurance Company increased its holdings in shares of Concert Pharmaceuticals by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 287 shares during the period. Finally, Airain ltd acquired a new stake in shares of Concert Pharmaceuticals in the 2nd quarter worth about $215,000. 65.36% of the stock is currently owned by institutional investors.
CNCE has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Concert Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 target price on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $23.00.
In related news, insider Value Fund L. P. Biotechnology bought 331,916 shares of the firm’s stock in a transaction that occurred on Thursday, October 19th. The stock was purchased at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ryan Lynch sold 3,500 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $14.51, for a total transaction of $50,785.00. Following the completion of the transaction, the insider now owns 9,500 shares of the company’s stock, valued at approximately $137,845. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
What are top analysts saying about Concert Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Concert Pharmaceuticals Inc and related companies.